A Phase 2 interventional study of Febuxostat and Placebo in Renal Impairment, sponsored by Takeda. Completed at 58 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-25.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Renal Insufficiency by Takeda — 1 open to participants now, 1 under way, none of them phase 3. Renal Insufficiency · Takeda.
Among the 12 studies in Renal Insufficiency by Takeda, this one is the 4th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2010, is one of 2 in phase 2, and was the 4th registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
Browse Renal Insufficiency studies →1 of the 12 studies in Renal Insufficiency by Takeda is open now, in 7 countries. Recruiting first, the newest first:
Takeda · Sites in Belgium, Estonia, France and 4 more countries
Ages 18+
By country, each count listing its studies:
Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 96 is above the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Median enrollment 48 across the 11 interventional studies, 10 across the 1 observational. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
1 of the studies in Renal Insufficiency by Takeda that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06243731TakedaA Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Renal Insufficiency by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the effect of febuxostat, once daily (QD) or twice daily (BID), on renal function in gout patients with elevated serum urate levels and who have moderate to severe renal impairment.
Gout is caused by high levels of uric acid in the body, and is associated with a broad range of conditions including heart disease, chronic kidney disease and high blood pressure. Hyperuricemia, which is defined as an elevation in serum urate levels, develops into gout when urate crystals form in the body and settle in joints and other organs.
Approximately 40-60% of patients with hyperuricemia and gout have some degree of renal impairment. Hyperuricemia has long been associated with renal disease, and chronic hyperuricemia as seen in gout can lead to deposition of urate crystals resulting in diminished renal function.
This study will evaluate the effect of febuxostat on the renal function of patients with hyperuricemia and gout and moderate to severe renal impairment.
All participants must have an average sitting blood pressure measurement less than 160 mmHg systolic and less than 95 mmHg diastolic. All participants must meet the American Rheumatism Association (ARA) diagnostic criteria for gout (subjects with tophi were excluded). Participants are expected to return to the site for approximately 10 visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo-matching capsules, orally, twice daily for up to 12 months.
Drug: Placebo
Febuxostat 30 mg, capsules, orally, twice daily (BID) for up to 12 months.
Drug: Febuxostat
Participants initially received febuxostat 40 mg, capsules, once daily (QD) and one placebo-matching capsule QD and remained on this dose for up to 12 months if their serum urate (sUA) was \<6.0 mg/dL at the Day 14 visit. Participants whose sUA was ≥6.0 mg/dL at the Day 14 visit received febuxostat 80 mg, capsule, QD, and one placebo-matching capsule QD at the Month 1 visit, and for the remainder of the study.
Drug: Febuxostat · Drug: Placebo
Febuxostat capsules
Also known as: Uloric, TMX-67
Febuxostat placebo-matching capsules
Change From Baseline to Month 12 in Serum Creatinine
Renal function was assessed by measuring the change from Baseline in serum creatinine. Analyses were conducted by the Central Laboratory.
Time frame: Baseline and Month 12
Change From Baseline to Month 12 in Estimated Glomerular Filtration Rate (eGFR)
Change from baseline to Month 12 in estimated Glomerular Filtration Rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula (as calculated by the central laboratory).
Time frame: Baseline and Month 12
Percentage of Participants With Serum Urate (sUA) Less Than 6 mg/dL at Month 12
Serum urate concentrations were determined using the enzymatic method as performed by the Central Laboratory.
Time frame: Month 12
Mean Clearance (CL/F) of Febuxostat at Steady State
Mean CL/F at steady state were estimated using a population pharmacokinetic (PK) approach, based on 2 PK samples collected prior to dosing, and 4 PK samples collected postdose.
Time frame: The 2 pre-dose PK samples collected were collected at any 2 of the following visits: Months 3, 6, 9, and/or 12, at -0.25 to 0 hours. The 4 postdose PK samples were collected at Months 3, 6, and/or 9, at 0.25; 0.75 to 2.0; 2.5 to 4.0; and 5 to 12 hours.
Mean Area Under the Concentration-Time Curve During the Dosing Interval (AUC[0-τ]) of Febuxostat at Steady State
Mean AUC during the dosing interval at steady state was estimated using a population pharmacokinetic (PK) approach, based on 2 PK samples collected prior to dosing, and 4 PK samples collected postdose.
Time frame: The 2 pre-dose PK samples collected were collected at any 2 of the following visits: Months 3, 6, 9, and/or 12, at -0.25 to 0 hours. The 4 postdose PK samples were collected at Months 3, 6, and/or 9, at 0.25; 0.75 to 2.0; 2.5 to 4.0; and 5 to 12 hours.
Participants took part in the study at 46 investigative sites in the United States from 09 April 2010 to 31 May 2012.
| Milestone | Placebo | Febuxostat 30 mg BID | Febuxostat 40/80 mg QD |
|---|---|---|---|
| Started | 32 | 32 | 32 |
| Completed | 15 | 17 | 24 |
| Not completed | 17 | 15 | 8 |
| Withdrew: Adverse event | 9 | 5 | 3 |
| Withdrew: Withdrawal by subject | 3 | 3 | 2 |
| Withdrew: Major protocol deviation | 3 | 3 | 0 |
| Withdrew: Lost to follow-up | 0 | 3 | 0 |
| Withdrew: Other | 2 | 1 | 3 |
Renal function was assessed by measuring the change from Baseline in serum creatinine. Analyses were conducted by the Central Laboratory.
| mg/dL | Placebo | Febuxostat 30 mg BID | Febuxostat 40/80 mg QD |
|---|---|---|---|
| Baseline | 2.52 ± 0.126 | 2.10 ± 0.126 | 2.22 ± 0.128 |
| Change from Baseline at Month 12 | 0.19 ± 0.094 | 0.09 ± 0.093 | 0.23 ± 0.094 |
Change from baseline to Month 12 in estimated Glomerular Filtration Rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula (as calculated by the central laboratory).
| mL/min/1.73m² | Placebo | Febuxostat 30 mg BID | Febuxostat 40/80 mg QD |
|---|---|---|---|
| Baseline | 29.31 ± 1.461 | 34.14 ± 1.461 | 34.08 ± 1.484 |
| Change from Baseline at Month 12 | -2.05 ± 1.198 | 0.33 ± 1.172 | -0.86 ± 0.190 |
Serum urate concentrations were determined using the enzymatic method as performed by the Central Laboratory.
| percentage of participants | Placebo | Febuxostat 30 mg BID | Febuxostat 40/80 mg QD |
|---|---|---|---|
| Percentage of Participants With Serum Urate (sUA) Less Than 6 mg/dL at Month 12 | 0 | 68.8 | 45.2 |
Mean CL/F at steady state were estimated using a population pharmacokinetic (PK) approach, based on 2 PK samples collected prior to dosing, and 4 PK samples collected postdose.
| liters/hour | Febuxostat 30 mg BID | Febuxostat 40 mg QD | Febuxostat 80 mg QD |
|---|---|---|---|
| Mean Clearance (CL/F) of Febuxostat at Steady State | 8.16 ± 2.31 | 8.71 ± 2.21 | 10.9 ± 4.70 |
Mean AUC during the dosing interval at steady state was estimated using a population pharmacokinetic (PK) approach, based on 2 PK samples collected prior to dosing, and 4 PK samples collected postdose.
| hr*µg/mL | Febuxostat 30 mg BID | Febuxostat 40 mg QD | Febuxostat 80 mg QD |
|---|---|---|---|
| Mean Area Under the Concentration-Time Curve During the Dosing Interval (AUC[0-τ]) of Febuxostat at Steady State | 3.98 ± 1.21 | 4.91 ± 1.29 | 8.21 ± 2.30 |
Collected over From first double-blind dose date and up to 30 days after the last dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 7/32 (21.9%) | 20/32 (62.5%) |
| Febuxostat 30 mg BID | — | 5/32 (15.6%) | 21/32 (65.6%) |
| Febuxostat 40/80 mg QD | — | 8/32 (25%) | 23/32 (71.9%) |
| Event | Placebo | Febuxostat 30 mg BID | Febuxostat 40/80 mg QD |
|---|---|---|---|
| Acute Myocardial InfarctionCardiac disorders | 2/32 | 0/32 | 1/32 |
| Atrial FibrillationCardiac disorders | 0/32 | 0/32 | 2/32 |
| Renal Failure AcuteRenal and urinary disorders | 2/32 | 1/32 | 1/32 |
| Cardiac Failure CongestiveCardiac disorders | 0/32 | 1/32 | 1/32 |
| Cardiogenic ShockCardiac disorders | 0/32 | 0/32 | 1/32 |
| Cardiac ArrestCardiac disorders | 1/32 | 0/32 | 0/32 |
| Ventricular FibrillationCardiac disorders | 0/32 | 0/32 | 1/32 |
| DiarrhoeaGastrointestinal disorders | 0/32 | 0/32 | 1/32 |
| Gastrooesophageal Reflux DiseaseGastrointestinal disorders | 0/32 | 1/32 | 0/32 |
| Adverse Drug ReactionGeneral disorders | 0/32 | 0/32 | 1/32 |
| Event | Placebo | Febuxostat 30 mg BID | Febuxostat 40/80 mg QD |
|---|---|---|---|
| Blood creatinine increasedInvestigations | 1/32 | 5/32 | 2/32 |
| DiarrhoeaGastrointestinal disorders | 4/32 | 2/32 | 4/32 |
| HyperkalaemiaMetabolism and nutrition disorders | 2/32 | 1/32 | 4/32 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/32 | 3/32 | 3/32 |
| NauseaGastrointestinal disorders | 3/32 | 2/32 | 0/32 |
| VomitingGastrointestinal disorders | 3/32 | 2/32 | 0/32 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/32 | 3/32 | 3/32 |
| BronchitisInfections and infestations | 2/32 | 3/32 | 0/32 |
| HypotensionVascular disorders | 0/32 | 0/32 | 3/32 |
| Back painMusculoskeletal and connective tissue disorders | 1/32 | 2/32 | 2/32 |
| Age Continuous(years) | Placebo | Febuxostat 30 mg BID | Febuxostat 40/80 mg QD | Total |
|---|---|---|---|---|
| Mean | 66.3 ± 12.05 | 67.3 ± 11.11 | 63.6 ± 8.15 | 65.7 ± 10.57 |
| Sex: Female, Male(Participants) | Placebo | Febuxostat 30 mg BID | Febuxostat 40/80 mg QD | Total |
|---|---|---|---|---|
| Female | 6 | 7 | 6 | 19 |
| Male | 26 | 25 | 26 | 77 |
| Race/Ethnicity, Customized(participants) | Placebo | Febuxostat 30 mg BID | Febuxostat 40/80 mg QD | Total |
|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 3 | 8 |
| Not Hispanic or Latino | 29 | 30 | 29 | 88 |
| Race/Ethnicity, Customized(participants) | Placebo | Febuxostat 30 mg BID | Febuxostat 40/80 mg QD | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 1 |
| Asian | 0 | 2 | 3 | 5 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 1 | 3 |
| Black or African American | 4 | 5 | 7 | 16 |
| White | 25 | 24 | 21 | 70 |
| Other | 1 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Placebo | Febuxostat 30 mg BID | Febuxostat 40/80 mg QD | Total |
|---|---|---|---|---|
| United States | 32 | 32 | 32 | 96 |
| Height(cm) | Placebo | Febuxostat 30 mg BID | Febuxostat 40/80 mg QD | Total |
|---|---|---|---|---|
| Mean | 172.6 ± 11.55 | 173.8 ± 9.60 | 172.8 ± 9.48 | 173.1 ± 10.16 |
| Weight(kg) | Placebo | Febuxostat 30 mg BID | Febuxostat 40/80 mg QD | Total |
|---|---|---|---|---|
| Mean | 100.7 ± 27.54 | 98.8 ± 19.84 | 102.6 ± 25.85 | 100.7 ± 24.42 |
| Body Mass Index (BMI)(kg/m^2) | Placebo | Febuxostat 30 mg BID | Febuxostat 40/80 mg QD | Total |
|---|---|---|---|---|
| Mean | 33.3 ± 6.36 | 32.8 ± 6.45 | 34.2 ± 7.30 | 33.4 ± 6.67 |
11 further baseline measures are reported on the registry.
The record gives a start of Apr 2010, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2013, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Febuxostat